It’s Official: CMS Repeals MCIT Rule, Leaves Door Open For Alternatives
Agency also scraps “reasonable and necessary” definition
Executive Summary
Despite industry efforts to save what it viewed as a boon to breakthrough medical technology, US Medicare has repealed the Medical Coverage for Innovative Technologies (MCIT) rule. In a more favorable move for industry, the agency scrapped a controversial qualifying definition for coverage eligibility.
You may also be interested in...
Industry Leaders Urge Congress, CMS To Expand Coverage Of Breakthrough Devices
Medtech leaders urged Congress to ensure coverage of breakthrough devices during a hearing by the House Ways and Means Subcommittee on Health.
Breakthrough Device Coverage Legislation Introduced In House
A bipartisan group of representatives introduced the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 to provide seniors access breakthrough devices.
Industry Advocates Cautiously Optimistic About CMS Proposal For Coverage Of New Devices
Trade groups like Medical Device Manufacturers Association and AdvaMed are optimistic for a reimbursement pathway for new medical devices but are awaiting further details.